Completed PHASE3 INTERVENTIONAL 1-arm NCT00206336

An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.

An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286)

Sponsor: Baylor College of Medicine

Conditions Tourette Syndrome

Interventions Topiramate (drug)

Updated 9 times since 2017 Last updated: Oct 5, 2017 Started: Oct 31, 2004 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00206336, this PHASE3 trial focuses on Tourette Syndrome and remains completed. Sponsored by Baylor College of Medicine, it has been updated 9 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Dec 2017 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Ortho-McNeil Janssen Scientific Affairs, LLC

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.